- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Amgen Buys Medigene Spin-Off Company Catherex
December 23, 2015.
Amgen (Thousand Oaks, CA) has acquired Catherex from Medigene (Munich, Germany) for an upfront payment of $10.5 million.
Medigene will receive about 40 percent of the payments from Amgen, while Catherex shareholders will receive the upfront payment plus milestone payments based on Amgen’s Imlygic, which was approved by FDA in October 2015 for the treatment of advanced, metastatic melanoma. Catherex, located in Philadelphia, PA, was spun off from Medigene in April 2010 with the development of a cancer-killing herpes simplex virus (oHSV).
Plan Ahead: Mastering Your AI Budget for 2025 Success
October 9th 2024Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.
